Joint Symposium 17  
Oncology & Theranostics Committee / European Association of Urology (EAU)  
Accessible on-demand at any time

Session Title
What to Do and Not Do in Prostate Imaging

Chairperson
Helle Zacho (Aalborg, Denmark)

Programme
22 min  
Tobias Maurer (Hamburg, Germany): What does Urology want to know from NM?

21 min  
Helle Zacho (Aalborg, Denmark): 9 years of PSMA - Where do we have Evidence for Being Helpful?

21 min  
Ali Afshar-Oromieh (Bern, Switzerland): 9 years of PSMA - Where do we have Evidence for not Being Helpful (yet)?

22 min  
Laura Evangelista (Padua, Italy): Prostate Cancer Imaging - Others than PSMA Ligands

3 min  
Summary by Chairperson

Educational Objectives
1. Urologist’s demands to Nuclear Medicine
2. Current evidence in PSMA imaging
3. Potential other ligands in prostate cancers imaging

Summary
In the recent years, PSMA targeted imaging has changed the management of prostate cancer patients. This session focuses on the current achievements in this field in generating evidence for being or not being helpful yet. Furthermore, it will give an insight in imaging of prostate cancer using other ligands than PSMA.

Key Words
Prostate Cancer, Prostate Specific membrane Antigen (PSMA), PET/CT; PET/MRI